2 results
Approved WMORecruiting
To compare the therapeutic benefit of maintenance pazopanib versus placebo after first line treatment of NSCLC.
Approved WMORecruiting
1. To evaluate the effect of brensocatib at 10 mg and 25 mg compared with placebo on the rate of pulmonary exacerbations (PEs) over the 52-week treatment period